Academic Journals Database
Disseminating quality controlled scientific knowledge

Injectable polyethylene glycol-fibrinogen hydrogel adjuvant improves survival and differentiation of transplanted mesoangioblasts in acute and chronic skeletal-muscle degeneration

ADD TO MY LIST
 
Author(s): Fuoco Claudia | Salvatori Maria | Biondo Antonella | Shapira-Schweitzer Keren | Santoleri Sabrina | Antonini Stefania | Bernardini Sergio | Tedesco Francesco Saverio | Cannata Stefano | Seliktar Dror | Cossu Giulio | Gargioli Cesare

Journal: Skeletal Muscle
ISSN 2044-5040

Volume: 2;
Issue: 1;
Start page: 24;
Date: 2012;
Original page

Keywords: Stem cells | Mesoangioblasts | Hydrogel | Muscular dystrophy | Muscle regeneration | Cell therapy | Tissue engineering

ABSTRACT
Abstract Background Cell-transplantation therapies have attracted attention as treatments for skeletal-muscle disorders; however, such research has been severely limited by poor cell survival. Tissue engineering offers a potential solution to this problem by providing biomaterial adjuvants that improve survival and engraftment of donor cells. Methods In this study, we investigated the use of intra-muscular transplantation of mesoangioblasts (vessel-associated progenitor cells), delivered with an injectable hydrogel biomaterial directly into the tibialis anterior (TA) muscle of acutely injured or dystrophic mice. The hydrogel cell carrier, made from a polyethylene glycol-fibrinogen (PF) matrix, is polymerized in situ together with mesoangioblasts to form a resorbable cellularized implant. Results Mice treated with PF and mesoangioblasts showed enhanced cell engraftment as a result of increased survival and differentiation compared with the same cell population injected in aqueous saline solution. Conclusion Both PF and mesoangioblasts are currently undergoing separate clinical trials: their combined use may increase chances of efficacy for localized disorders of skeletal muscle.
Affiliate Program      Why do you need a reservation system?